Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Retained Earnings: 2020-2024

Historic Retained Earnings for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$124.2 million.

  • SAB Biotherapeutics' Retained Earnings rose 16.64% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.0 million, marking a year-over-year increase of 16.64%. This contributed to the annual value of -$124.2 million for FY2024, which is 37.87% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Retained Earnings stood at -$124.2 million for FY2024, which was down 37.87% from -$90.1 million recorded in FY2023.
  • SAB Biotherapeutics' Retained Earnings' 5-year high stood at -$12.0 million during FY2020, with a 5-year trough of -$124.2 million in FY2024.
  • Its 3-year average for Retained Earnings is -$87.4 million, with a median of -$90.1 million in 2023.
  • Data for SAB Biotherapeutics' Retained Earnings shows a maximum YoY slumped of 143.06% (in 2021) over the last 5 years.
  • SAB Biotherapeutics' Retained Earnings (Yearly) stood at -$12.0 million in 2020, then crashed by 143.06% to -$29.1 million in 2021, then slumped by 64.34% to -$47.9 million in 2022, then tumbled by 88.14% to -$90.1 million in 2023, then slumped by 37.87% to -$124.2 million in 2024.